Erratum to 'Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis': [ESMO Open Volume 6, Issue 2, April 2021, 100088].

Peleg Hasson, S; Brezis, M R; Shachar, E; Shachar, S S; Wolf, I; Sonnenblick, A

Peleg Hasson, S; Brezis, M R; Shachar, E; Shachar, S S; Wolf, I; Sonnenblick, A.

Afiliación

Peleg Hasson S; Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Brezis MR; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shachar E; Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shachar SS; Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Wolf I; Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sonnenblick A; Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: amirson@tlvmc.gov.il.

ESMO Open ; 6(3): 100158, 2021 Jun.

Article en En | MEDLINE | ID: mdl-34144779

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: ESMO Open Año: 2021 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google